InflaRx (IFRX) Competitors $1.30 -0.05 (-3.70%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$1.30 0.00 (0.00%) As of 09/23/2025 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IFRX vs. ALT, DRUG, FDMT, AMRN, IMAB, SCPH, ALEC, RAPT, GALT, and ALDXShould you be buying InflaRx stock or one of its competitors? The main competitors of InflaRx include Altimmune (ALT), Bright Minds Biosciences (DRUG), 4D Molecular Therapeutics (FDMT), Amarin (AMRN), I-Mab (IMAB), scPharmaceuticals (SCPH), Alector (ALEC), Rapt Therapeutics (RAPT), Galectin Therapeutics (GALT), and Aldeyra Therapeutics (ALDX). These companies are all part of the "pharmaceutical products" industry. InflaRx vs. Its Competitors Altimmune Bright Minds Biosciences 4D Molecular Therapeutics Amarin I-Mab scPharmaceuticals Alector Rapt Therapeutics Galectin Therapeutics Aldeyra Therapeutics InflaRx (NASDAQ:IFRX) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings. Is IFRX or ALT more profitable? InflaRx has a net margin of 0.00% compared to Altimmune's net margin of -438,730.03%. Altimmune's return on equity of -62.63% beat InflaRx's return on equity.Company Net Margins Return on Equity Return on Assets InflaRxN/A -71.76% -57.68% Altimmune -438,730.03%-62.63%-55.29% Do analysts recommend IFRX or ALT? InflaRx presently has a consensus target price of $6.20, suggesting a potential upside of 376.92%. Altimmune has a consensus target price of $17.40, suggesting a potential upside of 359.10%. Given InflaRx's stronger consensus rating and higher possible upside, research analysts clearly believe InflaRx is more favorable than Altimmune.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InflaRx 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Altimmune 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Which has higher valuation & earnings, IFRX or ALT? InflaRx has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInflaRx$180K484.83-$49.85M-$0.80-1.63Altimmune$20K16,725.27-$95.06M-$1.18-3.21 Does the media favor IFRX or ALT? In the previous week, Altimmune had 21 more articles in the media than InflaRx. MarketBeat recorded 21 mentions for Altimmune and 0 mentions for InflaRx. InflaRx's average media sentiment score of 1.93 beat Altimmune's score of 0.13 indicating that InflaRx is being referred to more favorably in the media. Company Overall Sentiment InflaRx Very Positive Altimmune Neutral Which has more volatility and risk, IFRX or ALT? InflaRx has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Do insiders and institutionals have more ownership in IFRX or ALT? 42.4% of InflaRx shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 16.3% of InflaRx shares are held by company insiders. Comparatively, 4.4% of Altimmune shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryInflaRx beats Altimmune on 10 of the 15 factors compared between the two stocks. Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IFRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IFRX vs. The Competition Export to ExcelMetricInflaRxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$90.63M$3.16B$5.76B$10.51BDividend YieldN/A2.36%5.53%4.57%P/E Ratio-1.6221.0476.4326.62Price / Sales484.83252.12473.3192.90Price / CashN/A46.3537.4661.85Price / Book1.159.7813.616.45Net Income-$49.85M-$52.73M$3.29B$271.57M7 Day Performance10.17%3.16%1.87%2.61%1 Month Performance42.31%4.69%4.03%7.28%1 Year Performance-15.58%16.37%77.41%29.60% InflaRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IFRXInflaRx3.2288 of 5 stars$1.30-3.7%$6.20+376.9%-12.2%$90.63M$180K-1.6260Positive NewsALTAltimmune2.5204 of 5 stars$3.87+8.4%$17.40+349.6%-47.4%$315.08M$20K-3.2850High Trading VolumeDRUGBright Minds Biosciences3.2407 of 5 stars$50.15+12.2%$81.00+61.5%+4,103.0%$314.73MN/A-53.92N/AHigh Trading VolumeFDMT4D Molecular Therapeutics2.6364 of 5 stars$7.10+6.6%$30.40+328.2%-34.5%$311.04M$40K-2.01120AMRNAmarin0.6212 of 5 stars$14.92+2.2%$12.00-19.6%+34.8%$301.97M$228.61M-4.07360Positive NewsIMABI-Mab2.3918 of 5 stars$3.65-1.1%$7.00+91.8%+267.6%$301.33MN/A0.00380Gap DownSCPHscPharmaceuticals4.3899 of 5 stars$5.62-0.2%$7.78+38.5%+17.3%$300.07M$36.33M-3.1030ALECAlector3.9101 of 5 stars$3.13+6.1%$4.17+33.1%-41.7%$298.58M$100.56M-2.70270RAPTRapt Therapeutics3.4109 of 5 stars$20.50+13.9%$21.57+5.2%+48.9%$297.68MN/A-1.4580High Trading VolumeGALTGalectin Therapeutics1.9328 of 5 stars$4.64+1.1%$6.00+29.3%+76.8%$294.04MN/A-7.259ALDXAldeyra Therapeutics1.9758 of 5 stars$5.01+2.2%$9.50+89.6%-8.4%$293.49MN/A-5.8910 Related Companies and Tools Related Companies Altimmune Competitors Bright Minds Biosciences Competitors 4D Molecular Therapeutics Competitors Amarin Competitors I-Mab Competitors scPharmaceuticals Competitors Alector Competitors Rapt Therapeutics Competitors Galectin Therapeutics Competitors Aldeyra Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IFRX) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs This Nvidia’s Next Big Invention? (Picture Inside)Nvidia gave investors a chance to make more than 150 times their money with its AI chips known as graphic proc...InvestorPlace | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.